Abstract：Objective：To observe the clinical effect of the therapy of Shengmai capsules combined with chemotherapy on advanced lung adenocarcinoma. Methods： A total of 60 patients with advanced lung adenocarcinoma were selected and divided into the control group and the observation group according to the random number table method，with 27 and 33 cases in each group respectively. The control group was given chemotherapy of pemetrexed combined with cisplatin， and the observation group was additionally given Shengmai capsules based on the treatment of the control group. Both groups were continuously treated for three chemotherapy cycles， 21 days being a cycle. Before and after treatment， the quality of life which was valued， level of serum carcinoembryonic antigen(CEA)， toxicity and clinical effects in the two groups were evaluated. Results：The clinical effective rate was 60.61% in the observation group and 62.96% in the control group，there being no significance in the difference(P＞0.05). The disease control rate was 90.91% in the observation group and 88.89% in the control group， there being no significance in the difference(P＞0.05). Before treatment， there was no significant difference being found in the comparison of KPS scores between the two groups(P＞0.05)；after treatment，the KPS scores in the observation group was increased when compared with that before treatment(P＜0.05)，and was higher than that in the control group after treatment(P＜ 0.05). Before treatment，there was no significant difference being found in the comparison of level of serum CEA between the two groups(P＞0.05). After treatment， the CEA levels in both groups were decreased when compared with those before treatment(P＜0.05)， and the CEA level in the observation group was lower than that in control group(P＜0.05). During treatment， the incidence of adverse reactions was 42.42% in the observation group， and 77.78% in the control group，there being no significance in the difference(P＞0.05). Conclusion：The therapy of Shengmai capsules combined with pemetrexed and cisplatin regimen for patients with advanced lung adenocarcinoma is unable to significantly improve the clinical effect，but can reduce the CEA level，effectively improve the quality of life of patients，and does not increase the toxicity of treatment.